The authors regret that the following sentence on page 300 is inaccurate due to incorrect citations,

“There is a suggestion, from the results presented in the primary studies, that the risk of HZ in patients on tofacitinib may be even higher in patients with established RA who are sDMARD experienced and when tofacitinib is given in combination with methotrexate, with rates as high as between 5 and 8/100 PY. [60,74]”.

It has, however, been brought to the authors’ attention that the risk of zoster is indeed as high as 8/100 PY in certain subgroups such as in Asian study sites.

The authors would like to correct this sentence to read “There is a suggestion that the risk of HZ in patients on tofacitinib may be even higher in certain subgroups with rates as high as 8/100 PY. [Ref: http://acrabstracts.org/abstract/herpes-zoster-and-tofacitinib-the-risk-of-concomitant-nonbiologic-therapy/ ].”

The following sentence “Rates in patients enrolled at the Asian sites were significantly higher than at other sites, and higher dose, age and GC use were risk factors, with a higher risk early on in treatment [103]” remains the same.

The authors would like to apologise for any inconvenience caused.